A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco has discovered the underlying cause of gender differences in treatment-associated myocarditis after immune checkpoint inhibitor treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.
